Dr. John Mascarenhas: Preliminary Data Show Substantial Spleen, Symptom Improvement With Pelabresib, Ruxolitinib Combination in Myelofibrosis
John Mascarenhas, MD, discusses research finding that the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.